ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30) (Study 34237 (P06650)) (COMPLETED)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01044056
Recruitment Status : Completed
First Posted : January 7, 2010
Results First Posted : March 31, 2010
Last Update Posted : July 1, 2015
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

January 5, 2010
January 7, 2010
February 11, 2010
March 31, 2010
July 1, 2015
March 2004
June 2004   (Final data collection date for primary outcome measure)
  • Maximum Concentration (Cmax) (Pharmacokinentic Parameter (PK)) for All Subjects in the Pharmacokinetically Evaluable (ASPE) Group [ Time Frame: 21 days of active treatment and washout period thereafter ]
    Cmax was measured using ethinylstradiol serum concentration at several time points during the 21 days of active treatment and the washout thereafter.
  • Area Under the Curve (AUC) 0-21 Days (PK Parameter) Measured for the ASPE Group [ Time Frame: 21 days ]
    AUC 0-21 days was measured using ethinylestradiol serum concentration using a radio-immune assay at several time points during the 21 days of active treatment
  • AUC 0-tlast (PK Parameter) for the ASPE Group. [ Time Frame: 21 days of active treatment and washout period thereafter ]
    AUC 0-tlast was measured using ethinylestradiol serum concentrations using a radio-immune assay at several time points during the 21 days of active treatment and the washout period thereafter.
  • AUC 0-infinity (PK Parameter) for the ASPE Group. [ Time Frame: 21 days of active treatment and the washout period thereafter ]
    AUC 0-infinity was measured using ethinylestradiol serum concentration using a radio-immune assay at several time points during the 21 days of active treatment and the washout period thereafter. AUC 0-infinity was calculated as AUC 0-tlast extrapolated to infinity using the regression line from which t 1/2 was calculated.
To measure ethinyl estradiol (EE) serum concentration using a radio-immuno assay at several time points during the 21 days of active treatment and the washout thereafter. [ Time Frame: 21 days ]
Complete list of historical versions of study NCT01044056 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30) (Study 34237 (P06650)) (COMPLETED)
An Open-label, Randomized, Parallel Group Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30)
An open-label, randomized, parallel group trial in healthy female subjects to compare the pharmacokinetics of ethinyl estradiol (EE) of NuvaRing®, a contraceptive patch (EVRA(TM)) and an oral contraceptive (Microgynon® 30).
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Contraception
  • Drug: Levonorgestrel (LNG)/Ethinylestradiol (EE) oral contraceptive tablets
    LNG/EE oral contraceptive tablets (Microgynon® 30), 21 in total, containing 0.150 mg LNG and 0.030 mg EE per tablet administered once daily orally for 21 consecutive days.
    Other Names:
    • Microgynon
    • Batch Number: 374A 01K05
  • Drug: norelgestrominum and ethinylestradiol patch oral contraceptive patch
    A contraceptive patch (EVRA ™), one patch for 7 days for three consecutive weeks, 3 patches in total, applied on the lower abdomen. Dose: per patch 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.
    Other Names:
    • EVRA ™
    • Batch number : 0311264
  • Drug: Nuvaring ™ (etonorgestrel/ethinylestradiol)
    NuvaRing ™ , one ring for a period of 21 days, inserted vaginally. Dose: per ring 11.7 mg etonogestrel and 2.7 mg EE releasing a daily average amount of 0.120 mg etonogestrel and 0.015 mg EE.
  • Active Comparator: Levonorgestrel/ethinylestradiol oral contraceptive pill
    Microgynon(R), 1 tablet every day for 21 days; each tablet contains 0.150 mg levonorgestrel (LNG) and 0.030 mg ethinylestradiol (EE).
    Intervention: Drug: Levonorgestrel (LNG)/Ethinylestradiol (EE) oral contraceptive tablets
  • Active Comparator: Norelgestrominum and ethinylestradiol contraceptive patch
    Evra(TM), One patch applied on lower abdomen for 7 days for 3 consecutive weeks, 3 patches in total. Each patch contains 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.
    Intervention: Drug: norelgestrominum and ethinylestradiol patch oral contraceptive patch
  • Active Comparator: Etonogestrel and ethinylestradiol contraceptive vaginal ring
    Nuvaring(R), Place the ring in the vagina for 21 days, remove for one week. Repeat with new Ring. Dose: per ring 11.7 mg ENG and 2.7 mg EE releasing a daily average amount of 0.120 mg ENG and 0.015 mg EE.
    Intervention: Drug: Nuvaring ™ (etonorgestrel/ethinylestradiol)
van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005 Sep;72(3):168-74.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
24
Same as current
June 2004
June 2004   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject is at least 18 but not older than 40 years of age on Day 1 of treatment.
  • Subject has uterus and ovaria in situ
  • Subject who does not use hormonal contraception and is willing to use adequate nonhormonal contraceptive measures during the timeframe between screening and start treatment.
  • Subject is able and willing to refrain from caffeine and/or xanthine containing food and/or beverages (e.g. coffee, tea, cola or chocolate) from 24 hours before the first administration of the trial medication until the last PK blood sample.
  • Subject is willing not to consume grapefruit containing products 14 days prior to the start of the first administration of the trial medication until the last PK blood sample.
  • Subject is willing to refrain from smoking from 7 days prior to first administration of the trial medication until the last pharmacokinetic blood sample.
  • Subject is willing to refrain from alcohol containing products from 24 hours prior to first administration of the trial medication until the last pharmacokinetic blood sample.

Exclusion Criteria:

  • Contraindications for use of NuvaRing, contraceptive patch and oral contraceptive:
  • Presence or history of venous thrombosis, with or without the involvement of pulmonary embolism.
  • Presence or history of arterial thrombosis (e.g. cerebrovascular accident, myocardial infarction) or prodromi of a thrombosis (e.g. angina pectoris or transient ischaemic attack).
  • Known predisposition for venous or arterial thrombosis, with or without hereditary involvement such as Activated Protein C (APC) resistance, antithrombin-III deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinaemia, antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant) and Factor V Leiden mutation.
  • Diabetes mellitus with vascular involvement
  • The presence of a severe or multiple risk factor(s) for venous or arterial thrombosis (to be judged by the (sub-) investigator
  • Presence or history of severe hepatic disease as long as liver function values had not returned to normal or were judged to be clinically significant by the investigator.
  • Presence or history of liver tumours (benign or malignant).
  • Known or suspected malignant conditions of the genital organs or the breasts, if sex-steroid-influenced.
  • Undiagnosed vaginal bleeding.
  • Hypersensitivity to the active substances or to any of the excipients of NuvaRing, contraceptive patch and oral contraceptive.
  • Migraine with focal aura
  • Known or suspected pregnancy
  • Breastfeeding, or within 2 months after stopping breastfeeding on the day preceding the first administration of trial medication (Day -1).
  • Clinically significant abnormal laboratory, ECG (electrocardiogram) vital signs, physical and gynecological findings at screening.
  • A significant (history of) allergic or other serious disease, particularly gastrointestinal tract disease.
  • Smoking more than 5 cigarettes or 1 pipe or 1 cigar per day for a period of at least 3 months prior to screening.
  • Using any systemic medication (including over the counter (OTC) medication) during the 14 days prior to the day preceding the first administration of trial medication (Day -1), except for oral contraceptive used for synchronization and occasional Ibuprofen.
  • Used any drug or substance that is known to induce drug-metabolizing enzymes within two months prior to the start of synchronization.
  • Received a contraceptive by injection, an implant or hormonal intra-uterine device within 6 months of the day preceding the first administration of trial medication (Day -1), or a hormonal implant or hormonal intra-uterine device removed within 6 months of the day preceding the first administration of trial medication (Day -1).
  • Participated in a drug trial and was administered an investigational drug during the 90 days prior to start of synchronization.
  • Donated blood during the 90 days prior to the day preceding the first administration of trial medication (Day -1).
  • History (within the last 2 years) of excessive alcohol use, use of solvents or of drug abuse.
  • Positive drug test at screening and/or admission (Day -1), or a positive alcohol test at admission (Day -1).
  • Clinically significant abnormal cervical smear result (papaninecolaou (PAP) III or higher) at screening.
  • Acute or chronic hepatitis B/C or human immune deficiency virus (HIV) 1&2 infection.
Sexes Eligible for Study: Female
18 Years to 40 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01044056
P06650
No
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
June 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP